Avecho Biotechnology Limited (OEZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Avecho Biotechnology Limited (OEZ) has a cash flow conversion efficiency ratio of -0.334x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-808.80K ≈ $-945.58K USD) by net assets (€2.42 Million ≈ $2.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Avecho Biotechnology Limited for the company's overall valuation and market capitalisation.
Avecho Biotechnology Limited - Cash Flow Conversion Efficiency Trend (2013–2022)
This chart illustrates how Avecho Biotechnology Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Avecho Biotechnology Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avecho Biotechnology Limited ranked by their cash flow conversion efficiency. Explore Avecho Biotechnology Limited cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Terranet AB
ST:TERRNT-B
|
-0.162x |
|
Camellia Metal Co Ltd
TWO:2064
|
0.107x |
|
Handok Clean Tech Co. Ltd
KQ:256150
|
0.048x |
|
LakeShore Biopharma Co., Ltd
NASDAQ:LSB
|
-0.001x |
|
MST GOLF GROUP BERHAD
KLSE:5316
|
0.045x |
|
Union Materials Corp
KO:047400
|
0.080x |
|
Graines Voltz S.A
PA:GRVO
|
-0.242x |
|
Zuleika Gold Ltd
AU:ZAG
|
0.144x |
Annual Cash Flow Conversion Efficiency for Avecho Biotechnology Limited (2013–2022)
The table below shows the annual cash flow conversion efficiency of Avecho Biotechnology Limited from 2013 to 2022. View Avecho Biotechnology Limited (OEZ) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | €2.42 Million ≈ $2.83 Million |
€-1.67 Million ≈ $-1.95 Million |
-0.687x | -0.54% |
| 2021-12-31 | €4.54 Million ≈ $5.30 Million |
€-3.10 Million ≈ $-3.62 Million |
-0.683x | -27.33% |
| 2020-12-31 | €2.65 Million ≈ $3.10 Million |
€-1.42 Million ≈ $-1.66 Million |
-0.536x | -316.76% |
| 2019-12-31 | €4.76 Million ≈ $5.56 Million |
€1.18 Million ≈ $1.38 Million |
0.247x | +144.12% |
| 2018-12-31 | €3.90 Million ≈ $4.56 Million |
€-2.19 Million ≈ $-2.56 Million |
-0.561x | +44.06% |
| 2017-12-31 | €6.40 Million ≈ $7.49 Million |
€-6.42 Million ≈ $-7.51 Million |
-1.003x | -82.13% |
| 2016-12-31 | €11.65 Million ≈ $13.62 Million |
€-6.41 Million ≈ $-7.50 Million |
-0.551x | -82.96% |
| 2015-12-31 | €28.93 Million ≈ $33.82 Million |
€-8.71 Million ≈ $-10.18 Million |
-0.301x | -118.93% |
| 2014-12-31 | €49.03 Million ≈ $57.32 Million |
€-6.74 Million ≈ $-7.88 Million |
-0.137x | +36.70% |
| 2013-12-31 | €39.50 Million ≈ $46.18 Million |
€-8.58 Million ≈ $-10.03 Million |
-0.217x | -- |
About Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic f… Read more